Fertility preservation in ovarian tumours
- PMID: 30679952
- PMCID: PMC6345054
- DOI: 10.3332/ecancer.2018.885
Fertility preservation in ovarian tumours
Abstract
A considerable number of patients with a cancer diagnosis are of childbearing age and have not satisfied their desire for a family. Despite ovarian cancer (OC) usually occurring in older patients, 3%-14% are diagnosed at a fertile age with the overall 5-year survival rate being 91.2% in women ≤44 years of age when it is found at 1A-B stage. In this scenario, testing the safety and the efficacy of fertility sparing strategies in OC patients is very important overall in terms of quality of life. Unfortunately, the lack of randomised trials to validate conservative approaches does not guarantee the safety of fertility preservation strategies. However, evidence-based data from descriptive series suggest that in selected cases, the preservation of the uterus and at least one part of the ovary does not lead to a high risk of relapse. This conservative surgery helps to maintain organ function, giving patients of childbearing age the possibility to preserve their fertility. We hereby analysed the main evidence from the international literature on this topic in order to highlight the selected criteria for conservative management of OC patients, including healthy BRCA mutations carriers.
Keywords: fertility in cancer patients; fertility preservation; ovarian cancer; ovarian cancer survivors.
Figures
Similar articles
-
Fertility-sparing surgery in epithelial ovarian cancer.Future Oncol. 2016 Feb;12(3):389-98. doi: 10.2217/fon.15.319. Epub 2016 Jan 15. Future Oncol. 2016. PMID: 26768952 Review.
-
Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101966. doi: 10.1016/j.jogoh.2020.101966. Epub 2020 Nov 2. J Gynecol Obstet Hum Reprod. 2021. PMID: 33144266
-
Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.Ann Ital Chir. 2019;90:1-2. Ann Ital Chir. 2019. PMID: 30872561
-
Fertility-sparing treatment for epithelial ovarian cancer: a literature review.Chin Clin Oncol. 2020 Aug;9(4):48. doi: 10.21037/cco-20-38. Epub 2020 Jul 14. Chin Clin Oncol. 2020. PMID: 32692186 Review.
-
Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes.Eur J Surg Oncol. 2014 Apr;40(4):387-93. doi: 10.1016/j.ejso.2013.11.028. Epub 2013 Dec 13. Eur J Surg Oncol. 2014. PMID: 24368049 Review.
Cited by
-
Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours.Int J Environ Res Public Health. 2023 Jun 9;20(12):6089. doi: 10.3390/ijerph20126089. Int J Environ Res Public Health. 2023. PMID: 37372675 Free PMC article. Review.
-
Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer.Front Mol Biosci. 2022 Apr 14;9:770983. doi: 10.3389/fmolb.2022.770983. eCollection 2022. Front Mol Biosci. 2022. PMID: 35495636 Free PMC article.
-
Oncofertility and Fertility Preservation for Women with Gynecological Malignancies: Where Do We Stand Today?Biomolecules. 2024 Aug 3;14(8):943. doi: 10.3390/biom14080943. Biomolecules. 2024. PMID: 39199331 Free PMC article. Review.
-
Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.Biomedicines. 2020 Nov 30;8(12):554. doi: 10.3390/biomedicines8120554. Biomedicines. 2020. PMID: 33265938 Free PMC article. Review.
-
Reproductive outcomes in women with BRCA 1/2 germline mutations: A retrospective observational study and literature review.Open Med (Wars). 2024 Aug 20;19(1):20249999. doi: 10.1515/med-2024-9999. eCollection 2024. Open Med (Wars). 2024. PMID: 39176249 Free PMC article.
References
-
- American Cancer Society. 2016. [02/04/18]. [ www.cancer.org/cancer/ovariancancer/index]
Publication types
LinkOut - more resources
Full Text Sources